Showers v. Pfizer, Inc. (In re Pfizer Inc. Sec. Litig.)

BVLaw
Full Text of Court Cases
April 12, 2016

Access the Full Article

This article and its downloads are available with a subscription to any of these products:
It is also available in this product:
Already a subscriber or product owner?  Login
This article is also available for purchase. (13,700 words)   Add to Cart >>
Need help? Contact us:
1-503-479-8200 ext 2 or sales@bvresources.com
2834 Pharmaceutical Preparations
325412 Pharmaceutical Preparation Manufacturing
securities litigation
damages, daubert, expert testimony, admissibility, rule 702, securities fraud, loss causation
Showers v. Pfizer, Inc. (In re Pfizer Inc. Sec. Litig.)
2016 U.S. App. LEXIS 6622
US
Federal Court
2nd Circuit
United States Court of Appeals
Daniel R. Fischel (plaintiffs); Dr. Paul A. Gompers (defendants)
Livingston

Summary

Second Circuit says district court “went astray” when, under Daubert, it excluded entire loss causation and damages testimony of plaintiffs’ expert instead of just eliminating unreliable part; appeals court ruling revives securities fraud class action.
Showers v. Pfizer, Inc. (In re Pfizer Inc. Sec. Litig.)
PDF, Size: 384 KB

See Also

2nd Circuit Chafes at Wholesale Exclusion of Loss Causation Testimony

Legal and Court Case Update
June 2016

Second Circuit says district court “went astray” when, under Daubert, it excluded entire loss causation and damages testimony of plaintiffs’ expert instead of just eliminating unreliable part; appeals court ruling revives securities fraud class action.

This article also appears in:
The Comprehensive Guide to Economic Damages, Seventh Edition